Literature DB >> 27957235

Cardiac Resynchronization in Patients with Atrial Fibrillation.

S Serge Barold1, Bengt Herweg2.   

Abstract

Atrial fibrillation (AF) occurs in one of four patients undergoing cardiac resynchronization therapy (CRT).-Without special therapy, the prognosis of AF patients with CRT has been generally worse than those in sinus rhythm. The importance of a high percentage of biventricular pacing (BIV%) was confirmed in a large study where the mortality was inversely associated with BIV% both in the presence of normal sinus and atrial paced rhythm and with AF. The greatest reduction in mortality was observed with BIV% >98%. Patients with BIV% >99.6% experienced a 24% reduction in mortality (p < 0.001) while those with BIV% <94.8% had a 19% increase in mortality. The optimal BIV% cut-point was 98.7%. This cutoff would appear mandatory but it would be best to approach 100%. Careful evaluation of device interrogation data upon which the BiV% is based is essential because the memorized data can vastly overestimate the percentage of truly resynchronized beats since it does not account for fusion and pseudofusion between intrinsic (not paced) and paced beats. The recently published randomized CERTIFY trial provides unequivocal proof of the value of AV junctional (AVJ) ablation in CRT patients with AF. This trial confirmed the favorable results of AVJ ablation by many other studies and two important meta-analyses and therefore established the firm recommendation that the procedure should be performed in most, if not all, patients with permanent AF as well as those with frequent and prolonged episodes of paroxysmal AF. Patients after AVJ have improved mortality with a mortality similar to those in sinus rhythm. The AVJ ablation procedure carries the theoretical risk of device failure and death in pacemaker dependent patients. An inappropriate first ICD shock for AF seems to increase mortality. Increased long-term mortality after an inappropriate shock may be due to the underlying atrial arrhythmia substrate as opposed to the effect of the shock itself.

Entities:  

Keywords:  Ablation Of Atrioventricular Junction; Atrial Fibrillation; B Iventricular Pacing; Cardiac Resynchronization; Implantable Cardioverter Defibrillator

Year:  2015        PMID: 27957235      PMCID: PMC5135194          DOI: 10.4022/jafib.1383

Source DB:  PubMed          Journal:  J Atr Fibrillation        ISSN: 1941-6911


  55 in total

1.  Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation.

Authors:  C Leclercq; S Walker; C Linde; J Clementy; A J Marshall; P Ritter; P Djiane; P Mabo; T Levy; F Gadler; C Bailleul; J-C Daubert
Journal:  Eur Heart J       Date:  2002-11       Impact factor: 29.983

2.  2010 Focused Update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association.

Authors:  Kenneth Dickstein; Panos E Vardas; Angelo Auricchio; Jean-Claude Daubert; Cecilia Linde; John McMurray; Piotr Ponikowski; Silvia Giuliana Priori; Richard Sutton; Dirk J van Veldhuisen
Journal:  Eur Heart J       Date:  2010-08-27       Impact factor: 29.983

3.  Low inappropriate shock rates in patients with single- and dual/triple-chamber implantable cardioverter-defibrillators using a novel suite of detection algorithms: PainFree SST trial primary results.

Authors:  Angelo Auricchio; Edward J Schloss; Takashi Kurita; Albert Meijer; Bart Gerritse; Steven Zweibel; Faisal M AlSmadi; Charles T Leng; Laurence D Sterns
Journal:  Heart Rhythm       Date:  2015-01-28       Impact factor: 6.343

4.  The association between biventricular pacing and cardiac resynchronization therapy-defibrillator efficacy when compared with implantable cardioverter defibrillator on outcomes and reverse remodelling.

Authors:  Anne-Christine Ruwald; Valentina Kutyifa; Martin H Ruwald; Scott Solomon; James P Daubert; Christian Jons; Andrew Brenyo; Scott McNitt; Duc Do; Kenji Tanabe; Amin Al-Ahmad; Paul Wang; Arthur J Moss; Wojciech Zareba
Journal:  Eur Heart J       Date:  2014-08-11       Impact factor: 29.983

5.  Association of rate-controlled persistent atrial fibrillation with clinical outcome and ventricular remodelling in recipients of cardiac resynchronization therapy.

Authors:  Stephen B Wilton; Katherine M Kavanagh; Sandeep G Aggarwal; François Philippon; Raymond Yee; Karen Cowan; Derek V Exner
Journal:  Can J Cardiol       Date:  2011-09-09       Impact factor: 5.223

6.  Early detection of atrial high rate episodes predicts atrial fibrillation and thromboembolic events in patients with cardiac resynchronization therapy.

Authors:  Christoffer Tobias Witt; Mads Brix Kronborg; Ellen Aagaard Nohr; Peter Thomas Mortensen; Christian Gerdes; Jens Cosedis Nielsen
Journal:  Heart Rhythm       Date:  2015-07-08       Impact factor: 6.343

7.  Incidence of paroxysmal atrial tachycardias in patients treated with cardiac resynchronization therapy and continuously monitored by device diagnostics.

Authors:  C Leclercq; L Padeletti; R Cihák; P Ritter; G Milasinovic; D Gras; V Paul; I C Van Gelder; C Stellbrink; G Rieger; G Corbucci; B Albers; J C Daubert
Journal:  Europace       Date:  2010-01       Impact factor: 5.214

8.  Complete atrioventricular block does not reduce long-term mortality in patients with permanent atrial fibrillation treated with cardiac resynchronization therapy.

Authors:  José M Tolosana; Emilce Trucco; Malek Khatib; Adelina Doltra; Roger Borras; M Ángeles Castel; Antonio Berruezo; Elena Arbelo; Marta Sitges; Maria Matas; Eduard Guasch; Josep Brugada; Lluís Mont
Journal:  Eur J Heart Fail       Date:  2013-07-11       Impact factor: 15.534

9.  Detection of atrial high-rate events by continuous home monitoring: clinical significance in the heart failure-cardiac resynchronization therapy population.

Authors:  Nesan Shanmugam; Annegret Boerdlein; Jochen Proff; Peter Ong; Oswaldo Valencia; Sebastian K G Maier; Wolfgang R Bauer; Vince Paul; Stefan Sack
Journal:  Europace       Date:  2011-09-20       Impact factor: 5.214

10.  Long-term survival in patients undergoing cardiac resynchronization therapy: the importance of performing atrio-ventricular junction ablation in patients with permanent atrial fibrillation.

Authors:  Maurizio Gasparini; Angelo Auricchio; Marco Metra; François Regoli; Cecilia Fantoni; Barbara Lamp; Antonio Curnis; Juergen Vogt; Catherine Klersy
Journal:  Eur Heart J       Date:  2008-04-04       Impact factor: 29.983

View more
  4 in total

Review 1.  Comparison of survival for cardiac resynchronization therapy in atrial fibrillation patients with or without atrio-ventricular junction ablation and patients in sinus rhythm: a systematic review and network meta-analysis.

Authors:  Yangjing Xue; Jinsheng Wang; Jiaoni Wang; Saroj Thapa; Kaiyu Huang; Yangpei Peng; Lu Qian; Jiwu Li; Kangting Ji
Journal:  Heart Fail Rev       Date:  2019-05       Impact factor: 4.214

Review 2.  Atrial fibrillation is associated with sudden cardiac death: a systematic review and meta-analysis.

Authors:  Pattara Rattanawong; Sikarin Upala; Tanawan Riangwiwat; Veeravich Jaruvongvanich; Anawin Sanguankeo; Wasawat Vutthikraivit; Eugene H Chung
Journal:  J Interv Card Electrophysiol       Date:  2018-01-13       Impact factor: 1.900

3.  Overview of Current Strategies Aiming at Improving Response to Cardiac Resynchronization Therapy.

Authors:  Yakup Yunus Yamantürk; Başar Candemir; Emir Baskovski; Kerim Esenboğa
Journal:  Anatol J Cardiol       Date:  2022-05       Impact factor: 1.475

4.  Relationship between device-detected subclinical atrial fibrillation and heart failure in patients with cardiac resynchronization therapy defibrillator.

Authors:  Shuhei Arai; Mitsuharu Kawamura; Toshihiko Gokan; Kosuke Yoshikawa; Ko Ogawa; Akinori Ochi; Yumi Munetsugu; Hiroyuki Ito; Toshiro Shinke
Journal:  Clin Cardiol       Date:  2020-09-29       Impact factor: 2.882

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.